Diabetes and risk of tumors: Oncologic considerations;Diabetes és rákkockázat az onkológus szemszögébol

Orvosi Hetilap

Volumn 152, Issue 29, 2011, Pages 1144-1155

  Rosta, András ^a,b  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b NONE   (Hungary)

Author keywords

diabetes mellitus; insulin; metformin; risk of malignancy

Indexed keywords

ANTIDIABETIC AGENT; INSULIN GLARGINE; METFORMIN;

APOPTOSIS; ARTICLE; CANCER MORTALITY; CANCER RISK; CELL PROLIFERATION; COMORBIDITY; DRUG ACTIVITY; HUMAN; HYPERINSULINEMIA; INCIDENCE; MALIGNANT NEOPLASTIC DISEASE; MITOGENESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; RISK FACTOR;

EID: 79959925441     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2011.29158     Document Type: Article

References (89)

1. IDF Diabetes Atlas (article online), 2009. 4th ed. Brussels, Bel gium, International Diabetes Federation. Available from www.diabetesatlas.org. Accessed I April 2010.
2. World Cancer Report: 2008 (article online), 2008. Eds: Boyle, P. Bernard, L. Cedex, France, World Health Organization, International Agency for Research on Cancer. Available from http:// www.iarc.fr/en/publications/pdfs-online/wcr/ index.php. Accessed 1 April 2010.
3. Wideroff, L., Gridley, G., Mellemkjaer, L. és mtsai: Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J. Natl. Cancer Inst., 1997, 89, 1360-1365. (Pubitemid 27418027) (Pubitemid 27418027)
4. Chaw, W-H., Gridky, G., Nyren, O. és mtsai: Risk of pancreatic cancer following diabetes mellitus: A nationwide cohort study in Sweden. J. Natl. Cancer Inst., 1995, 87, 930-931.
5. Huxley, R., Ansary-Moghaddam, A., Berington de Gonzalez, A. és mtsai: Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies. Br. J. Cancer, 2005, 92, 2076-2083. (Pubitemid 40897433) (Pubitemid 40897433)
6. Larsson, S. C., Orsini, N., Walk, A.: Diabetes mellitus and risk of colorectal cancer: A meta-analysis. J. Natl. Cancer Inst., 2005, 97, 1679-1687. (Pubitemid 41672234) (Pubitemid 41672234)
7. Larsson, S. C., Mantzoros, C. S., Wolk, A.: Diabetes mellitus and risk of breast cancer: A meta-analysis. Int. J. Cancer, 2007, 121, 856-862. (Pubitemid 47106217) (Pubitemid 47106217)
8. Weiderpass, E., Gridky, G., Persson, I. és mtsai: Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J. Cancer, 1997, 71, 360-363. (Pubitemid 27224297) (Pubitemid 27224297)
9. Bonovas, S., Filioussi, K., Tsantes, A.: Diabetes mellitus and risk of prostate cancer: A metaanalysis. Diabctologia, 2004, 47, 1071-1078. (Pubitemid 38918167)
10. Pierce, B. L., Plymate, S., Ostrande, E. A. és mtsai: Diabetes mellitus and prostate cancer risk. Prostate, 2008, 68, 1126-1132. (Pubitemid 351875184)
11. Leitzmann, M. F., Ahn, J., Albanes, D. és mtsai: Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Sreening Trial. Cancer Causes Control, 2008, 19, 1267-1276.
12. Peairs, K. S., Barone, B. B., Snyder, C. F. és mtsai: Diabetes mellitus and breast cancer outcomes: A systematic review and meta analysis. J. Clin. Oncol, 2011, 29, 40-46.
13. Coughlin, S. S., Calle, E. E., Teras, L. R. és mtsai: Diabetes mellitus as a predictor of cancer mortality in a large cohort: of US adults. Am. J. Epidemiol., 2004, 159, 1160-1167. (Pubitemid 38747263) (Pubitemid 38747263)
14. Barone, B. B., Teh, H. C., Snyder, C. F. és mtsai: Postoperative mortality in cancer patients with preexisting diabetes: Systematic review and meta-analysis. Diabetes Care, 2010, 33, 931-939.
15. Barone, B. B., Teh, H. C., Snyder, C. P. és mtsai: Long-term allcause mortality in cancer patients with preexisting diabetes mellitus: A systematic review and metaanalysis. JAMA, 2008, 300, 2754-2764.
16. Barone, B. B., Teh, H. C., Snyder, C. F. és mtsai: Long-term allcause mortality in cancer patients with preexisting diabetes mellitus: A systematic review and metaanalysis. JAMA, 2008, 300, 2754-2764.
17. Zhou, X. H., Qiao, Q., Zetkelius, B. és mtsai: Diabetes, prediabetes and cancer mortality. Diabctologia, 2010, 53, 1867-1876.
18. Hassan, M. M., Cttrley, S. A., Li, D. és mtsai: Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer, 2010, 116, 1938-1946.
19. Carstensen, B., Witte, D. R, Friis, S.: Diabetes and insulin duration and cancer incidence: A register linkage study in Denmark. Diabetologia, 2010, 5.3 (Suppl. 1) , S67.
20. Calle, E. E., Kaaks, R.: Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer, 2004, 4, 579-591. (Pubitemid 39025053) (Pubitemid 39025053)
21. Calle, E. E., Rodriguez, C., Walker-Thurmond, K. és mtsai: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med., 2003, 348, 1625-1638. (Pubitemid 36459468) (Pubitemid 36459468)
22. Hagymási K., Tulassay Zs.: Az elhízás szerepe a vastagbéldaganatok kialakulásában. Orv. Hetil., 2007, 148, 2411-2415.
23. Currie, C. J., Poole, C. D, Gale, E. A. M.: The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabctologia, 2009, 52, 1766-1777.
24. Jemai, A., Siegel, R., Ward, E. és mtsai: Cancer statistics, 2009. CA Cancer J. Clin., 2009, 59, 225-249.
25. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007 (article online), 2008. Atlanta, Georgia, Centers for Disease Control and Prevention. Available from http://www.cdc.gov/ diabetes/pubs/ pdf/ndfs...2007.pdf. Accessed I April 2010.
26. Schienkiewitz, A., Schulze, M. B., Hoffmann, K. és mtsai: Body mass index history and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Am. J. Clin. Nutr., 2006, 84, 427-433. (Pubitemid 44699156) (Pubitemid 44699156)
27. Rosenbloom, A. L., Joe, J. R., Toung, R. S. és mtsai: Emerging epidemic of type 2 diabetes in youth. Diabetes Care, 1999, 22, 345-354. (Pubitemid 29056933) (Pubitemid 29056933)
28. Renehan, A. G., Tyson, M., Egger, M. és mtsai: Body mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet, 2008, 371, 569-578. (Pubitemid 351232031) (Pubitemid 351232031)
29. Calle, E. E., Kaaks, R.: Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer, 2004, 4, 579-591. (Pubitemid 39025053) (Pubitemid 39025053)
30. Suba, Zs., Barabás, J., Szabé, Gy. és mtsa: Increased prevalence of diabetes and obesity in patients with salivary gland tumors. Diabet. Care, 2005, 28, 228-230.
31. Key, T. J., Appleby, P. N., Reeves, G. K. és mtsai: Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J. Natl. Cancer Inst., 2003, 95, 1218-1226. (Pubitemid 37069552) (Pubitemid 37069552)
32. Hamman, R. F., Wing, R. R., Edelstem, S. L. és mtsai: Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care, 2006, 29, 2102-2107. (Pubitemid 44871194) (Pubitemid 44871194)
33. Buchwald, H., Estok, R., Fahrbach, K. és mtsai: Weight and type 2 diabetes after bariatric surgery: Systematic review and metaanalysis. Am. J. Med., 2009, 122, 248-256.
34. Eliassen, A. H., Colditz, G. A., Rosner, B. és mtsai: Adult weightchange and risk of postmenopausal, breast cancer. JAMA, 2006, 296, 193-201. (Pubitemid 44050373) (Pubitemid 44050373)
35. Guidelines Advisory Committee: American Cancer Society guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA. Cancer J. Clin., 2006, 56, 254-281.
36. Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective (article online), 2007. London, World Cancer Research Fund, American Institute for Cancer Research. Available from http://www.dietaiid.can. ce.rreport.org/. Accessed 1 April 2010.
37. George, S. M., Mayne, S. T, Leitzmann, M. F. és mtsai: Dietary glycemic index, glycemic load, and risk of cancer: A prospective cohort study. Am. J. Epidemiol., 2009, 169, 462-472.
38. Lee, I. M.: Physical activity and cancer prevention-data from epidemiologic studies. Med. Sci. Sports Exerc., 2003, 35, 1823-1827.
39. Willi, C., Bodenmann, P., Ghali, W. A. és mtsai: Active smoking and the risk of type 2 diabetes: A systematic review and metaanalysis. JAMA, 2007, 298, 2654-2664. (Pubitemid 350254957) (Pubitemid 350254957)
40. Howard, A. A., Arruten, J. H., Gourevitch, M. N.: Effect, of alcohol consumption on diabetes mellitus: A systematic review. Ann. Intern. Med., 2004, 140, 211-219.
41. Baliunas, D. O., Taylor, B. J., Irving, H. és mtsai: Alcohol as a risk factor for type 2 diabetes: A systematic review and meta-analysis. Diabetes Care, 2009, 32, 2123-2132.
42. Gupta, K., Krishnaswamy, G., Karnad, A. és mtsai: Insulin: A novel factor in cancerogenesis. Am. J. Med. Sci., 2002, 323, 140-145.
43. Pollak, M.: Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer, 2008, 8, 915-928.
44. Goalstone, M. L., Carel, K., Ijtitner, J. W. és mtsai: Insulin, stimulates the phosphorylation, and activity of farnesyltransferase via the Ras-Map kinase pathway. Endocrinology, 1997, 138, 5119-5124. (Pubitemid 27509668) (Pubitemid 27509668)
45. Frasca, F., Pandini, G., Sciacca, L. és mtsai: The role of insulin receptors and IGF-1 receptors in cancer and other diseases. Arch. Physiol. Biochem., 2008, 114, 23-37. (Pubitemid 351998752) (Pubitemid 351998752)
46. Sandow, J.: Growth effects of insulin and insulin analogues. Arch. Physiol. Biochem., 2009, 115, 72-85.
47. Wolpin, B. M., Meyerhardt, J. A., Chan, A. T. és mtsai: Insulin, the insulin like growth factor axis, and mortality in patients with nonmetastatic colorectal, cancer. J. Clin. Oncol., 2009, 27, 176-185.
48. Bowker, S. L., Majumdar, S. R., Veugelers, P. és mtsa: Increased, cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care, 2006, 29, 254-258. (Pubitemid 44106500) (Pubitemid 44106500)
49. Becker, S., DOSSMS, L., Kaaks, R.: Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch. Physiol. Biochem., 2009, 115, 86-96.
50. Muntoni, S., Muntoni, S., Draznin, B.: Effects of chronic hyperinsulinemia in insulin resistant patients. Curr. Diab. Rep., 2008, 8, 233-238.
51. Halmos T., Suba I.: A metabolikus szindróma és a 2-es típusú diabetes mellitus mint, rosszindulatú daganatra hajlamosító állapotok. Orv. Hetil., 2008, 149, 2403-2411.
52. Suba Zs., Ujpál M.: Az inzulinrezisztencia és a daganat. összefüggései. Magyar Ontologia, 2006, 50, 127-135.
53. Suba Zs., Barabás J., Takács D. és mtsai: Az inzulinrezisztencia és a nyálmirigydaganatok epidemiológiai összeruggései. Orv. Hetil., 2005, 146, 1727-1732.
54. Verheus, M., Peeters, P. H., Rinaldi, S. és mtsai: Serum C-peptide levels and breast cancer risk: results from, the European Prospective Investigation into Cancer and Nutrition (EPIC). Int. J. Cancer, 2006, 119, 659-667. (Pubitemid 43955721) (Pubitemid 43955721)
55. Jing, M. A., Giovanucci, E., Pollak, M. és mtsa: A. prospective study of plasma C-peptide and colorectal cancer risk in men. J. Natl. Cancer Inst., 2004, 96, 546-553. (Pubitemid 38559579) (Pubitemid 38559579)
56. Powell, D. R., Suwanichkul, A., Cubbage, M. L. és mtsai: Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1. J. Biol. Chem., 1991, 266, 18868-18876. (Pubitemid 21908164) (Pubitemid 21908164)
57. Belfiore, A.: The role of insulinreceptor isoforms and hybrid insulin/IGF-1 receptors in human cancer. Curr. Pharm. Des., 2007, 13, 671-686. (Pubitemid 46510744)
58. Abe, R., Yamagishi, S.: AGE-RAGE system and carcinogenesis. Curr. Pharm. Des., 2008, 14, 940-945. (Pubitemid 351753280) (Pubitemid 351753280)
59. Valko, M., Izakovic, M., Mazur, M. és mtsai: Role of oxygen radicals in DNA damage and cancer incidence. Mol. Cell. Biochem., 2004, 266, 37-56. (Pubitemid 39562306) (Pubitemid 39562306)
60. Somogyi A.: Oxidatív stressz diabetes mellitusban. In: Diabetes mellitus, elmélet és klinikum. Szerk.: Halmos T., Jermendy Gy. Medicina Könyvkiadó, Budapest, 2002, 179-195.
61. Rapp, K., Schroeder, J., Klenk, J. és mtsai: Fasting blood, glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabctologia, 2006, 49, 945-952.
62. Stattin, P., Björ, O., Ferrari, P. és mtsai: Prospective study of hyperglycemia and cancer risk. Diabet. Care, 2007, 30, 561-567. (Pubitemid 46354334) (Pubitemid 46354334)
63. Kershaw, E. E., Flier, J. S.: Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab., 2004, 89, 2548-2556. (Pubitemid 38766330) (Pubitemid 38766330)
64. Gero L.: Diabetes, diabetes-kezelés és neoplasia. Biztonságosak-e az antidiabetikus készítmények? Diabetologia Hungarica, 2009, 17, 313-322.
65. Alimova, I. N., Liu, B., Fan, Z. és mtsai: Metformin inhibits breast, cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle, 2009, 8, 909-915.
66. Pierce, E. L., Walsh, M. C., Cejas, P. J. és mtsai: Enhancing CD8 T cell memory by modulating fatty acid metabolism. Nature, 2009, 460, 103-107.
67. Dowling, R. J., Zakikhani, M., Fantus, I. G. és mtsai: Metformin inhibits mammalian target of rapamycin dependent translation initiation in breast cancer cells. Cancer Res., 2007, 67, 10804-10812. (Pubitemid 350145909) (Pubitemid 350145909)
68. Hirsch, H A., Iliopoulos, D., Tsichlis, P. N. és mtsa: Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res., 2009, 69, 7507-7511.
69. Evans, J. M., Donnelly, L. A., Emslie-Smith, A. M. és mtsai: Metformin and reduced, risk of cancer in diabetic patients. Br. Med. J., 2005, 330, 1304-1305. (Pubitemid 40813563) (Pubitemid 40813563)
70. DeCensi, A., Puntoni, M., Goodwin, P. és mtsai: Metformin and cancer risk in diabetic patients: A systematic review and metaanalysis. Cancer Prev. Res. (Phila), 2010, 3, 1451-1461.
71. Landman, G. W, Kleefstra, N., van Hateren, K.J. és mtsai: Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care, 2010, 33, 322-326.
72. Govindarjan, R., Ratnasinghe, L., Simmonds, D. L. és mtsai: Thiazolidinediones and the risk of lung, prostate and colon cancer in patients with diabetes. J. Clin. Oncol., 2007, 25, 1461-1462.
73. Panigrahy, D., Huang, S., Kieran, M. W. és mtsa: PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol. Ther., 2005, 4, 687-693. (Pubitemid 41351164) (Pubitemid 41351164)
74. Ondrey, F.: Peroxisome proliferatoractivated receptor gamma pathway targeting in carcinogenesis: implications for chemoprcvention. Clin. Cancer Res., 2009, 15, 2-8.
75. Monami, M., Lamanna, C., Marchionni, N. és mtsa: Rosiglitazone and risk of cancer: A meta-analysis of randomized clinical trials. Diabetes Care, 2008, 31, 1455-1460.
76. Bowker, S. L., Majumdar, S. R., Veugelers, P. és mtsa: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin, Diabetes Care, 2006, 29, 254-258. (Pubitemid 44106500) (Pubitemid 44106500)
77. Monami, M., Lamanna, C., Balzi, D. és mtsai: Sulphonylurcas and cancer: A case-control study. Acta Diabetol., 2009, 46, 279-284.
78. Shukla, A., Grisouard, J., Ehemann, V. és mtsai: Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr. Relat. Cancer, 2009, 16, 429-441,
79. Weinstein, D., Simon, M., Tehezkel, E. és mtsai: Insulin analogues display IGF-I-like mitogenic and antiapoptotic activities in cultured cancer cells. Diabetes Metab. Res. Rev., 2009, 25, 1-49.
80. Kurtzhals, P., Schäffer, L., Sørensen, A. és mtsai: Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed, for clinical use. Diabetes, 2000, 49, 999-1005. (Pubitemid 30349423) (Pubitemid 30349423)
81. Sandow, J.: Growth effects of insulin and insulin analogues. Arch. Physiol. Biochem., 2009, 115, 72-85.
82. Hemkens, L. G., Grouven, U., Bender, R. és mtsai: Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study. Diabctologia, 2009, 52, 1732-1744.
83. Jonasson, J. M., Ljung, R., Talbäck, M. és mtsai: Insulin glargine use and short-term incidence of malignancies - a population based follow-up study in Sweden. Diabetologia, 2009, 52, 1745-1754.
84. Calhoun, H. M., SDRN Epidemiology Group: Use of insulin glargine and cancer incidence in Scotland: A study from the Scottish Diabetes Research. Network Epidemiology Group. Diabetologia, 2009, 52, 1755-1765.
85. Rosenstock, J., Fonseca, V., McGill, J. B. és mtsai: Similar risk of malignancy with insulin glargine and neutral protamine Hage dorn (NPH) insulin in patients with, type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia, 2009, 52, 1971-1973.
86. Smith, U., Gale, E. A.: Does diabetes therapy influence the risk of cancer? Diabetologia, 2009, 52, 1699-1708.
87. Gerstein, H. C.: Does insulin therapy promote, reduce, or have a neutral effect on cancers? JAMA, 2010, 303, 446-447.
88. Owens, D. R., Rosenstock, J., Bolli, G. B.: Insulin glargine and cancer: cause and effect unproven. Pract. Diab. Int., 2009, 26, 256-257.
89. Pocock, S. J., Smeeth, L.: Insulin glargine and malignancy: An unwarranted alarm. Lancet, 2009, 374, 511-513.